Kanae Mukai, MD
Cardiovascular Disease · Salinas, CANPI 1366677577
Payments from drug & device makers
Across 251 payments — averaging $169.53 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Canon Medical Systems USA, Inc.$34K
- Abbott$3K
- Boston Scientific$2K
- Cleerly, Inc.$496
- Heartflow, Inc.$406
- Novo Nordisk$358
- plus $2K from 27 others
What the payments were for
- Consulting fees$21,72051%
- Speaking & faculty fees$6,50015%
- Grants$950%
- Travel & lodging$7,93619%
- Food & beverage$6,30215%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Canon Medical Systems USA, Inc. | 44 | $33,742 |
| Abbott | 42 | $3,059 |
| Boston Scientific | 72 | $2,094 |
| Cleerly, Inc. | 9 | $496 |
| Heartflow, Inc. | 4 | $406 |
| Novo Nordisk | 9 | $358 |
| E.r. Squibb & Sons, L.L.C. | 14 | $306 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 6 | $258 |
| Medtronic | 4 | $236 |
| Shockwave Medical, Inc | 1 | $163 |
| Edwards Lifesciences | 2 | $153 |
| Canon Medical Informatics, Inc. | 2 | $149 |
| Novartis | 7 | $138 |
| AstraZeneca | 3 | $137 |
| Pfizer | 4 | $122 |
| Alnylam Pharmaceuticals Inc. | 4 | $94 |
| W. L. Gore & Associates, Inc. | 1 | $92 |
| Perspectum Diagnostics Ltd | 1 | $81 |
| Johnson & Johnson | 4 | $75 |
| Irhythm Technologies, Inc. | 2 | $58 |
| Merck | 2 | $45 |
| Regeneron Healthcare Solutions, Inc. | 2 | $39 |
| Abiomed | 1 | $36 |
| Amgen | 2 | $32 |
| Kowa Pharmaceuticals America, Inc. | 1 | $27 |
| Lantheus Medical Imaging, Inc. | 1 | $25 |
| Bayer | 1 | $24 |
| Boehringer Ingelheim | 1 | $22 |
| Biotronik Inc. | 1 | $21 |
| Kiniksa Pharmaceuticals International, PLC | 1 | $19 |
| Atricure, Inc. | 1 | $17 |
| Kestra Medical Technology Services, Inc. | 1 | $16 |
| Vifor Pharma, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- TOSHIBA SUPERCONDUCTING MRI SYSTEM Vantage Titan$9,720
- Vantage Orian$7,428
- Vantage Galan 3T$5,500
- MI (Molecular Imaging)$2,500
- GENERAL NON-EQUIPMENT$2,500
- Watchman$1,163
- MitraClip System$750
- CANON INC.$295
- LifeVest$234
- Cleerly Ischemia$215
- Cleerly Labs$215
- PRESSUREWIRE$173
- Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter$163
- FFRct$148
- Wegovy$125
- COREVALVE EVOLUT R$122
- TRICLIP$122
- LOKELMA$111
- Edwards SAPIEN 3 Ultra Transcatheter Heart Valve$104
How this compares
$42,553 in reported general payments places this provider in the 85th percentile of 2,184 cardiovascular disease providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 237 | $297,739 |
| Praluent PenAlirocumab | 77 | $67,583 |
| Repatha SureclickEvolocumab | 51 | $57,533 |
| XareltoRivaroxaban | 35 | $46,985 |
| EntrestoSacubitril/Valsartan | 28 | $45,393 |
| JardianceEmpagliflozin | 15 | $21,292 |
| BrilintaTicagrelor | 14 | $15,755 |
| VascepaIcosapent Ethyl | 12 | $10,180 |
| Rosuvastatin Calcium | 426 | $8,305 |
| Isosorbide Dinitrate | 77 | $7,217 |
| Amiodarone Hcl | 103 | $6,699 |
| Ezetimibe | 142 | $4,385 |
| Metoprolol Succinate | 230 | $4,101 |
| Bumetanide | 45 | $2,865 |
| Atorvastatin Calcium | 270 | $2,861 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $122 | $297,739237 claims |
| Johnson & JohnsonXarelto | $75 | $46,98535 claims |
| NovartisEntresto | $138 | $45,39328 claims |
| Boehringer IngelheimJardiance | $22 | $21,29215 claims |
| AstraZenecaBrilinta | $137 | $15,75514 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 2,184 cardiovascular disease providers in California.
Other cardiovascular disease in Salinas
- Ted LoveHillsborough$102.8M
- Matthew BudoffTorrance$11.3M
- Lori DanielsSan Diego$10.2M
- Paul KurthSanta Barbara$6.1M
- Michael BlumSan Francisco$5.5M
- Tony ChouSan Francisco$5.2M
- Jason RogersSacramento$5.1M
- Yu-Ping WangStanford$3.8M
- Yogesh PaliwalPomona$3.3M
- Farhad RafiiWest Hills$3.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.